# The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM

> **NCT03111238** · PHASE3 · TERMINATED · sponsor: **Ixaka Ltd** · enrollment: 3 (actual)

## Conditions studied

- Peripheral Arterial Disease (PAD)
- Diabetes Mellitus (DM)
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Cardiovascular Disease
- Critical Limb Ischemia (CLI)

## Interventions

- **DRUG:** REX-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03111238
- **Lead sponsor:** Ixaka Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-05
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Stopped due to inactivity
- **Last updated:** 2021-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03111238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03111238, "The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03111238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*